US-based Alitair Pharmaceuticals has retained Finn, Warnke & Gayton to sell two Alitair patents and an associated royalty stream at a sealed bid sale on 24 May 2013. The first patent, which was issued in 2012, covers the use of ion ...
Tags: Alitair Pharmaceuticals, Health, Medicine
Alitair Pharmaceuticals has gained a notice of allowance from the US Patent and Trademark Office for its ion exchange resin platform drug delivery technology, REA. Alitair has out-licensed two product candidates utilizing its REA platform ...
Tags: Alitair Pharmaceuticals, REA Drug Delivery Technology, US Patent